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Abstract
Introduction Excess of incidence rates is the expected
consequence of service screening. The aim of this paper is to
estimate the quota attributable to overdiagnosis in the breast
cancer screening programmes in Northern and Central Italy.
Methods All patients with breast cancer diagnosed between 50
and 74 years who were resident in screening areas in the six
years before and five years after the start of the screening
programme were included. We calculated a corrected-for-lead-
time number of observed cases for each calendar year. The
number of observed incident cases was reduced by the number
of screen-detected cases in that year and incremented by the
estimated number of screen-detected cases that would have
arisen clinically in that year.
Results In total we included 13,519 and 13,999 breast cancer
cases diagnosed in the pre-screening and screening years,
respectively. In total, the excess ratio of observed to predicted
in situ and invasive cases was 36.2%. After correction for lead
time the excess ratio was 4.6% (95% confidence interval 2 to
7%) and for invasive cases only it was 3.2% (95% confidence
interval 1 to 6%).
Conclusion The remaining excess of cancers after individual
correction for lead time was lower than 5%.
Introduction
Breast cancer service screening programmes have been
implemented on a regional basis in several Italian areas. Most
screening programmes are participants in the national survey
promoted by the Italian Group for Mammography Screening
CI = confidence interval; MST = mean sojourn time.Breast Cancer Research    Vol 8 No 6    Paci et al.
Page 2 of 9
(page number not for citation purposes)
[1] and have collected performance data in accordance with
the European guidelines for breast cancer screening [2,3].
Early diagnosis of breast cancer and excess incidence are the
expected consequences of breast cancer screening. The pos-
sible detection at screening of breast cancers that would not
have been diagnosed in the absence of screening over a sub-
ject's lifetime has been defined as overdiagnosis [4,5].
In this paper we present observational data from a large Italian
study – the Impact Study – in which we apply a statistical
model for monitoring service screening to forecast the possi-
ble occurrence of overdiagnosis. This study is based on the
evaluation of individual cases and not on aggregated data,
which have been used in most studies evaluating service
screening so far.
Materials and methods
The Impact Study
The Impact Study included breast cancers diagnosed
between 1986 and 2001 in women aged 40 to 79 years who
were resident in 17 areas mainly located in Central and North-
ern Italy. Breast cancers were included in accordance with the
International Agency for Research on Cancer rules for cancer
registration [6]. In situ carcinomas were included, and death
certificate only (DCO) cases were excluded. All registry-based
breast cancer cases were linked to the screening file and
divided up by detection method. We classified cases as either
screen detected or not screen detected, and as invited or
uninvited to screening.
In this paper we have included areas with at least five years of
screening data: Torino, Parma, Ferrara, Modena, Romagna
and Firenze (Table 1). In situ carcinomas were missing in a few
pre-screening years in two registries. In these cases, the inci-
dence of in situ carcinoma was estimated from age-specific
data of the two subsequent pre-screening years. Incidence
rates were calculated from data on populations by area, year
and age class produced by the National Statistics Institute.
The pooled annual trend of incidence in the pre-screening
period was modelled through a two-step Poisson analysis
process. In the first step, a Poisson regression model (model
1) including age (annual, range from 40 to 79 years) and cal-
endar time (continuous, year) was fitted to the available pre-
screening incidence data for each area. Interaction terms
between age and calendar period were not found statistically
significant in any area (P = 0.05). In the second step, a pooled
Poisson model (model 2) including age (continuous), calendar
time (continuous, year) and area as independent variables,
based on observed and estimated by model 1, predicted rates
for each area for the period 1986 to 2001. Throughout this
paper we have presented time on a screening time scale,
where 1 is the first year of the screening programme. We con-
sider two periods: six years of pre-screening (years -5 to 0)
and five years of screening (years 1 to 5).
Screening process and correction for lead time
Screening works by detecting breast cancer in the early phase
of its natural history; the period during which a tumour is in the
pre-clinical detectable phase is known as its sojourn time. In
several studies an estimate of sojourn time has been fitted with
an exponential distribution [7]. Following this, the estimated
mean sojourn time (MST) is 1/λ, where λ is the average of the
exponential distribution (that is, the rate of progression from
the preclinical to the clinical phase, as estimated from screen-
ing data).
Given these assumptions, the MST is also the estimate of the
average lead time of screen-detected cases. It is therefore
possible to estimate the probability that a tumour currently
detected at screening in the pre-clinical phase would have of
progressing to the clinical phase in each year after detection
in the absence of screening. If we suppose that a breast
cancer is diagnosed at time t2 in the preclinical detectable
phase (see Figure 1), then it is possible to estimate the prob-
Table 1
Pre-screening and screening time periods of the study, and number of breast cancer cases
Register Study period Start year of 
screening
Pre-screening cases Screening cases Total cases
Torino 1986–1996 1992 3,017 3,185 6,202
Parma 1991–2001 1997 1,567 1,714 3,281
Ferrara 1991–2001 1997 1,539 1,400 2,939
Modena 1989–1999 1995 2,283 2,056 4,339
Romagna 1990–2000 1996 3,029 3,405 6,434
Firenze 1986–1995 1991 2,084 2,239 4,323
Totals 13,519 13,999 27,518Available online http://breast-cancer-research.com/content/8/6/R68
Page 3 of 9
(page number not for citation purposes)
ability that the case would have of surfacing as symptomatic
each year afterwards. Some screen-detected cases will be
expected to arise in the short term (that is, they have short lead
time) and others in the long term (a long lead time).
Thus it is possible to calculate the probability that each
screen-detected case would have been identified clinically
each year after detection until a defined time, such as the end
of the study period. The sum of these probabilities over all the
screen-detected cases, year by year, gives an estimate of the
number of screen-detected cases that would have arisen clin-
ically each year. The corrected-for-lead-time number of
observed cases for each calendar year corresponds to the
number of observed incident cases reduced by the number of
screen-detected cases in that year, and incremented by the
estimated number of screen-detected cases (in whatever
year) that would have arisen clinically in that year [8]. Following
the terminology suggested by Etzioni [9], the number of incre-
mental cases (that is, the number of screen-detected cases)
should be compensated for by the number of decremental
cases (that is, the number of screen-detected cases that
would have arisen clinically). In a certain number of years these
figures should equalise (assuming no overdiagnosis). The cor-
rected-for-lead-time cases should be compared with the pre-
dicted number in the absence of screening, and the
percentage excess after correction for lead time is an indicator
of overdiagnosis, given the lead time estimate.
In screening literature, there is quite a good agreement
between estimates of the mean sojourn time of breast cancer:
between three and four years, and longer at higher ages. In
this paper we modelled with MST durations of 3.7 and 4.2
years for women aged 50 to 59 years and 60 to 74 years at
screen detection, respectively [10].
In the upper part of the graph in Figure 2, a hypothetical
number of screen-detected cases at the first and two subse-
quent screenings has been shown, reflecting the experience
of women starting at 64 years and repeating the test at 66 and
68 years, and thereafter leaving the programme. The excess of
incidence resulting from the earlier detection will continue until
the women stop having a mammogram. The decremental
cases expected each year were estimated (under the assump-
tions of the duration and distribution of the MST) and are
shown below the time axis. On this basis, it is evident that 90%
of incremental cases are expected to be decremental in at
least 11 years starting from the year of incidence.
Figure 1
Natural history of breast cancer and screening Natural history of breast cancer and screening.
Figure 2
Incremental and decremental cases in a cohort of women aged 64 years at entry Incremental and decremental cases in a cohort of women aged 64 years at entry.Breast Cancer Research    Vol 8 No 6    Paci et al.
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It should also be noted that, contrary to what is intuitively
expected, a large part of the decremental cases will have been
diagnosed clinically until screening was ongoing; in our exam-
ple, 65% of the incremental cases at the three screening
rounds will have been decremental over the time for which the
woman was continuing her screening regimen. Decremental
cases that would determine the incidence rate decrease after
the cessation of screening at 70 years of age are only a small
proportion of the total incremental cases. Furthermore, the
incidence rate decrease expected after the end of screening
might be less relevant than expected because women will con-
tinue to receive mammograms outside the screening
programme.
Results
In total we included 13,519 breast cancer cases diagnosed in
the pre-screening years (corresponding to years from -5 to 0).
In the five years of screening (years 1 to 5), 13,999 cases
were included from the six cancer registries.
Pooling the pre-screening incidence data from the six areas,
the annual percentage change in the pooled incidence trend
was 1.2% (95% confidence interval (CI) 0.8 to 1.6) for all
breast cancers and 0.9% (95% CI 0.5 to 1.3) for invasive
breast cancers only.
Figure 3 shows the excess of incidence observed in the study
screening programmes for women aged 50 to 74 at diagnosis,
over the screening time scale. Population-based incidence
rates are presented by method of detection (not invited and
invited, divided into screen detected and not screen
detected). At the end of five years from time 0, 68.2% of the
50 to 74-year-old cases (77.7% of the cases aged 50 to 69
years) had received an invitation to be screened, and 37.5%
(42.8% of the cases aged 50 to 69 years) were detected at
screening.
In Figure 4 the incidence rates are presented by year relative
to the start of screening and compared with the predicted
rates in the absence of screening and with the data corrected
for lead time. Results excluding in situ carcinomas were similar
(data not shown).
In Table 2 the results are reported by 5-year age groups for
women aged 50 to 74 years at diagnosis and compared with
the predicted number of cases in the absence of screening. In
total, in the first 5 years of screening, the ratio of observed to
predicted in situ and invasive cases was 136.2% (95% CI
134 to 139%), a 36% excess of cases. After correction for
lead time, the ratio for in situ and invasive cases was 104.6%
(95% CI 102 to 107%), and for invasive cases only it was
103.2% (95% CI 101 to 106%).
In Figure 5 the excess of breast cancer incidence is presented
by 5-year age group at diagnosis, comparing incidence rates
in the period 1 to 3 years since start (this is equivalent to the
period of the first round of screening) and 4 to 5 years after the
start (subsequent rounds), and incidence rates after the
correction for lead time. The dotted line shows the predicted
incidence rates in the absence of screening. The 50 to 54-
year-old women showed an excess of 7.4% in both the first
and subsequent rounds. Indeed, in the period 4 to 5 years
after the start, women aged 50 to 54 years were mostly new
entries (prevalent screening).
Figure 3
Breast cancer incidence rates by method of detection, on the screening time scale Breast cancer incidence rates by method of detection, on the screening time scale. The participants were aged 50 to 74 years. SD, screen 
detected; NSD, not screen detected.Available online http://breast-cancer-research.com/content/8/6/R68
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Figure 4
Breast cancer incidence rates predicted, observed, and observed corrected for lead time Breast cancer incidence rates predicted, observed, and observed corrected for lead time. The participants were aged 50 to 74 years.
Table 2
Observed, predicted, screen-detected breast cancer cases and observed corrected-for-lead-time cases, by age group
Age group 
(years)
O P O/P Screen-
detected
Oc Oc/P 95% CI, Oc/P
50–54 1,957 1,328.1 147.4 749 1,426 107.4 102–113
55–59 2,017 1,418.8 142.2 950 1,410 99.4 94–105
60–64 2,192 1,555.8 140.9 995 1,566 100.7 96–106
65–69 2,340 1,605.8 145.7 1,031 1,697 105.7 101–111
70–74 1,788 1,646.9 108.6 127 1,807 109.7 105–115
50–74 10,294 7,555.3 136.2 3,852 7,906 104.6 102–107
O, observed; P, predicted; Oc, observed corrected for lead time; CI, confidence interval.
Figure 5
Breast cancer incidence rates by age group and years since the start of the screening Breast cancer incidence rates by age group and years since the start of the screening.Breast Cancer Research    Vol 8 No 6    Paci et al.
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In the following analysis, breast cancer incidence rates were
estimated with a cohort approach grouped by age at the
beginning of the screening programme. Women are aging
over the screening time scale, so the predicted number of
cases is expected to increase over time. In Figure 6 results are
presented by five year age group and compared with the pre-
dicted and the corrected-for-lead-time cases. With the cohort
method, the observed rates corrected for lead time corre-
sponded very closely to the predicted ones, particularly for the
55 to 64-year-old age group. Women aged 65 to 69 years
showed an increase in incidence, reaching the highest of all
groups' peaks at prevalence screening. Whereas some of
them could have continued screening at older ages, we
observed a sharp decrease in the incidence in women within
the five year follow-up period. The incidence rate decreases
close to the level of the expected incidence.
Discussion
Breast cancer service screening in Italy started in the late
1990s, and at the moment only a few areas have more than
five years of follow-up. An excess of incidence was evident
immediately after the start of screening and this increase was
strictly related to the incremental number of screen-detected
cases. The excess of incidence was especially evident in
women older than 65 years at the first screening test (preva-
lent). This result confirms the possibility of a risk of overdiag-
nosis in older age groups – a risk that is higher in
correspondence to the peak of breast cancer detection at
prevalence screening. Incidence rates decreased at the inci-
dent screening, but they did not return to the predicted inci-
dence rates. For women aged 70 to 74 years at the beginning
of the screening programme (a group of women not involved
in the screening process in the first period of screening), there
was no evidence of changes in the incidence rate when com-
paring observed and predicted rates. The excess of incidence
due to the incremental detection, which is the intended effect
of screening, should correspond to a decrement of the number
of cases arising in subsequent years. However, as we have
shown in the example of women aged 64 years at their first
screening and continuing to receive screening until 69 years
old, the decrement in the number of excess cases starts imme-
diately and would occur until screening is ongoing. It could
therefore not be seen in the observed rates.
To document the residual excess of cases (that is, the over-
diagnosis due to screening) follow-up studies should extend
over many years from the start of a programme. However, in
the absence of a control and given the increasing uncertainty
over time in the prediction of long-term incidence trends, eval-
uation is difficult.
MacCann and colleagues [11] have highlighted the peak of
incidence observed in the 60 to 64-year-old age group at prev-
alent screening in the UK programme and the subsequent
decline in the observed incidence about six years after the
start. An approach taking into account lead time and using a
model correcting observed data for lead time was used by
Paci and colleagues [8] in the evaluation of the excess of
incidence and overdiagnosis in the Florence City programme.
In that analysis, the probability of cases being detected before
or after the study period was estimated. The method of quan-
tification used in the present paper is similar, but we have mod-
elled the decremental number of cases over the years after the
screen detection.
Randomised population-based trials have recently been
reviewed by Moss [12], suggesting no overdiagnosis related
to the incident screening and an excess of 10 to 15% at seven
to eight years of follow-up from the start in trials with no control
group screening. Data on randomised trials have been
updated by the recent results published by the Malmö, Gote-
borg and Two County studies [13-15]. The two Swedish stud-
ies confirmed the absence of excess of incidence in trials in
which the control group was screened at the end of the study
period. In their analysis, taking into account the statistical
adjustment for lead time, Duffy and colleagues showed a risk
of overdiagnosis lower than 5%.
The Malmö trial showed, at the end of 15 years of follow-up
after the study's end, a residual excess equal to 10% of cases
in the screened group [13]. There were two major problems in
the evaluation of the long-term residual excess of cases in the
screened arm. First, because 60% of the women died in the
Malmö study, there is the need to assess the impact of com-
peting causes of death on the overdiagnosis estimate. Sec-
ond, women could have mammograms within or outside the
programme (including after the last age for screening and dif-
ferential screening practice between groups), so it is difficult
to assess the excess over such a long period.
The statistical modelling used in this paper is based on two
major assumptions. The first is that the predicted trends can
be estimated from pre-screening data. The second assump-
tion concerns the estimation of sojourn time and its exponen-
tial distribution, and, thus, of the lead time. There is much
evidence supporting the estimates we have adopted in this
paper, and models for the assessment of breast cancer
screening have been shown to be quite consistent in predict-
ing observed results. Recent modelling of breast cancer
screening with several statistical models has confirmed the
consistency of our knowledge of the natural history of the dis-
ease [14].
However, estimates are always subject to criticism. For these
reasons we performed a sensitivity estimate. With the upper
limit (4.8 years) of 95% CI of the lead time estimate for 50 to
74-year-old women, the estimate of overdiagnosis was 102.8,
including the in situ carcinomas; that is, an excess of 3%. To
quantify further the residual excess of incidence, namely the
exclusion of overdiagnosis, the lead time needed to equaliseAvailable online http://breast-cancer-research.com/content/8/6/R68
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Figure 6
Breast cancer incidence rates predicted, observed, and observed corrected for lead time Breast cancer incidence rates predicted, observed, and observed corrected for lead time. The age groups at first invitation were as follows: (a) 50 to 
54 years; (b) 55 to 59 years; (c) 60 to 64 years; (d) 65 to 69 years; (e) 70 to 74 years.Breast Cancer Research    Vol 8 No 6    Paci et al.
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the predicted and corrected-for-lead-time cases (an
observed:expected ratio of 1) was calculated as 6.0 years.
This value is too long for the current estimates, although a sim-
ilar value was recently estimated in the Norway screening pro-
gramme [15].
Birth cohort approach has been shown by Moller and col-
leagues [16] as the more informative approach to demonstrate
the decrease in the incidence rate after the end of the screen-
ing regimen. In the large programmes of North Europe, as in
our study, a smaller number of women continue with screening
when they are over the age of 70 years.
The cohort analysis comparing the predicted with the cor-
rected-for-lead-time cases confirmed the possible risk of over-
diagnosis for women having a mammogram aged 65 to 69
years at entry. This age group showed the highest peak of inci-
dence at prevalent screening.
The strength of this evaluation of the impact of breast cancer
screening lies in its study of population-based characteristics
and from the collection of individual screening histories. In
most studies published so far, results have been estimated
from aggregated data and without the possibility of a subject-
specific attribution of the individual lead time. This, along with
the methodological difference related to the probabilistic mod-
elling in our paper of the postponement of cases, might
account for the difference between our findings and those of
Jonsson and colleagues [17], who showed a minimal change
in the excess of incidence after correction for lead time. There
is also the possibility of confounding with other effects on inci-
dence in the paper by Jonsson and colleagues, as acknowl-
edged in their discussion.
Conclusion
In the screening age groups (ages 50 to 74 years) the excess
of incidence was 36.2% and after correction for lead time the
remaining excess of in situ and invasive carcinomas was 4.6%
(95% CI 2 to 7%), less than 5%. Excluding in situ carcinomas
the excess was 3.2% (95% CI 1 to 6%).
Longer follow-up is needed to confirm this estimate, but at five
years since the programme started, the risk of overdiagnosis is
modest, considering that it is not possible at the moment to
distinguish on an individual basis which cancer will progress
and which will not. Further research is needed to improve our
understanding of the markers of tumour progression and so
enhance our ability to avoid over-treatment of screen-detected
cases.
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